Boceprevir dosing for late responders and null responders: The role of bridging data between treatment-naïve and -experienced subjects

Hepatology

Volumn 57, Issue 3, 2013, Pages 903-907

  Florian, Jeffry ^a   Jadhav, Pravin R ^a   Amur, Shashi ^a   Ayala, Ruben ^a   Harrington, Patrick ^a   Mishra, Poonam ^a   O'Rear, Jules ^a   Pacanowski, Michael ^a   Robertson, Sarah ^a   Singer, Mary ^a   Soon, Greg ^a   Zeng, Wen ^a   Murray, Jeffrey ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ARTICLE; DRUG EFFECT; HEPATITIS C; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; STUDY DESIGN; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG MONITORING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PROLINE; RIBAVIRIN; UNITED STATES;

EID: 84874456956     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25843     Document Type: Article

References (11)

1. ® as of 5/13/11 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf Accessed September 2, 2011.
2. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 201131; 364: 1195-1206.
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
4. Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Interferon responsiveness does not change in experienced hepatitis C subjects: implications for drug development and clinical decisions. HEPATOLOGY [submitted].
5. Topiramate label. In: Food and Drug Administration, Center for Drug Evaluation and Research: (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021014s015s019s022s024s025s027s028, 285s009s013s015s018s019s020s022lbl.pdf).
6. Topiramate label. In: Food and Drug Administration, Center for Drug Evaluation and Research: (http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020505s042, 844s036lbl.pdf).
7. Li F, Nandy P, Chien S, Noel GJ, Tornoe CW. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalation anthrax in children. Antimicrob Agents Chemother 2010; 54: 375-379.
8. Lee JY, Garnett CE, Gobburu JV, Bhattaram VA, Brar S, Earp JC, et al. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 2011; 50: 627-35.
9. Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. In: Food and Drug Administration, Center for Drug Evaluation and Research: (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryinformation/Guidances/ucm078749.pdf).
10. Antiviral Drugs Advisory Committee: FDA Briefing Information for the April 27, 2011 Meeting of the Antiviral Drugs Advisory Committee. In: US Food and Drug Administration, Center for Drug Evaluation and Research: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252341.pdf. Accessed September 2, 2011.
11. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.